Jonathan Dunn, MD
Cardiovascular Disease · South Miami, FLNPI 1942566526
Payments from drug & device makers
Across 308 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$707
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$640
- E.r. Squibb & Sons, L.L.C.$535
- Pfizer$527
- Johnson & Johnson$499
- Boston Scientific$473
- plus $4K from 28 others
What the payments were for
- Food & beverage$7,173100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 53 | $707 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $640 |
| E.r. Squibb & Sons, L.L.C. | 28 | $535 |
| Pfizer | 26 | $527 |
| Johnson & Johnson | 24 | $499 |
| Boston Scientific | 5 | $473 |
| Amarin Pharma, Inc. | 27 | $464 |
| Medtronic(2 entities) | 6 | $422 |
| AstraZeneca | 20 | $362 |
| Novo Nordisk | 15 | $344 |
| Novartis | 13 | $262 |
| Abbott | 6 | $243 |
| Heartflow, Inc. | 3 | $214 |
| Shockwave Medical, Inc | 1 | $163 |
| Boehringer Ingelheim | 6 | $150 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $114 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $108 |
| Sanofi-aventis U.S. LLC | 6 | $108 |
| Bayer | 4 | $96 |
| Impulse Dynamics (USA) Inc. | 4 | $86 |
| Lilly USA, LLC | 5 | $82 |
| Astellas Pharma US Inc | 4 | $73 |
| Atricure, Inc. | 3 | $73 |
| Arbor Pharmaceuticals, Inc. | 5 | $67 |
| Regeneron Healthcare Solutions, Inc. | 4 | $64 |
| Alnylam Pharmaceuticals Inc. | 2 | $51 |
| Akcea Therapeutics, Inc. | 3 | $46 |
| Kestra Medical Technology Services, Inc. | 2 | $41 |
| Scpharmaceuticals Inc. | 1 | $38 |
| Lexicon Pharmaceuticals, Inc. | 2 | $38 |
| Merck | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Cvrx, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,184 in reported general payments places this provider in the 65th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 241 | $320,245 |
| Repatha SureclickEvolocumab | 294 | $257,476 |
| EntrestoSacubitril/Valsartan | 101 | $135,848 |
| OzempicSemaglutide | 53 | $96,089 |
| FarxigaDapagliflozin Propanediol | 65 | $73,482 |
| XareltoRivaroxaban | 52 | $60,645 |
| MounjaroTirzepatide | 55 | $57,354 |
| JardianceEmpagliflozin | 33 | $41,229 |
| Praluent PenAlirocumab | 58 | $35,444 |
| VascepaIcosapent Ethyl | 51 | $31,188 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $13,317 |
| BrilintaTicagrelor | 13 | $13,163 |
| Clonidine | 59 | $9,834 |
| Repatha SyringeEvolocumab | 16 | $9,524 |
| Rosuvastatin Calcium | 640 | $9,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $527 | $320,245241 claims |
| NovartisEntresto | $262 | $135,848101 claims |
| Novo NordiskOzempic | $344 | $96,08953 claims |
| AstraZenecaFarxiga, Brilinta | $362 | $86,64578 claims |
| Johnson & JohnsonXarelto | $499 | $60,64552 claims |
| Lilly USA, LLCMounjaro | $82 | $57,35455 claims |
| Boehringer IngelheimJardiance | $150 | $41,22933 claims |
| Sanofi-aventis U.S. LLCMultaq | $108 | $7,68111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in South Miami
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
- Duccio BaldariWellington$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.